Skip to main content
Clinical Trials/NCT01505205
NCT01505205
Completed
Not Applicable

Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors

Guangxi Medical University0 sites60 target enrollmentApril 2011

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing Approach
Sponsor
Guangxi Medical University
Enrollment
60
Status
Completed
Last Updated
14 years ago

Overview

Brief Summary

Mutations of tumor-related genes are dynamic. Gastrointestinal stromal tumor cells often are obviously more invasive in case of recurrence. The great majority of relapses may be associated with secondary mutation in the GIST related genes. Full gene sequences of c-KIT、PDGFRA and DOG1, which is extracted from the specimen cells of repeated surgical resection or biopsy tissue in GIST patients with postoperative recurrence, are analyzed with the screening-sequencing approach, in order to investigate the characteristics and variations associated with the different gene mutations of c-KIT、PDGFRA and DOG1 in GIST patients and be likely to find out the evolutionary pattern, try to learn the facts about the effect of tyrosine kinase inhibitors on the GIST related genes, make a survey of any association of c-KIT、PDGFRA and DOG1 gene mutations and provide the basis for seeking molecular marker of GIST for monitoring course of disease, and offer a theoretical basis and new therapeutic strategies for application of clinical treatment.

Registry
clinicaltrials.gov
Start Date
April 2011
End Date
June 2011
Last Updated
14 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Guangxi Medical University
Responsible Party
Principal Investigator
Principal Investigator

Zhang Haitian

M.D.

Guangxi Medical University

Eligibility Criteria

Inclusion Criteria

  • patients with Gist at the Department of Gastrointestinal and Glands Surgery of the First Affiliated Hospital of Guangxi Medical University in China.

Exclusion Criteria

  • patients with hepatitis and tuberculosis

Outcomes

Primary Outcomes

Not specified

Similar Trials